“Change is the process by which the future invades our lives.” – Alvin Toffler
Although Mr. Toffler wasn’t referring to Novo Nordisk (NYSE: NVO) who reported results this morning, he could have been. This company which once ruled the diabetes kingdom is caught in the vortex of departing from the past and repurposing itself for the future. Not only does this involve change in people but a change in how the company does business. The people part is easy, the rest well let’s just say change is tough.
As we anticipated sales of the core insulin products . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.